Browse ZNF473

Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=Stable component of Cajal bodies (CBs). Colocalizes with SMN, coilin and U7 snRNA.
Domain PF01352 KRAB box
Function

Involved in histone 3'-end pre-mRNA processing by associating with U7 snRNP and interacting with SLBP/pre-mRNA complex. Increases histone 3'-end pre-mRNA processing but has no effect on U7 snRNP levels, when overexpressed. Required for cell cycle progression from G1 to S phases.

> Gene Ontology
 
Biological Process GO:0006353 DNA-templated transcription, termination
GO:0006369 termination of RNA polymerase II transcription
GO:0006397 mRNA processing
GO:0006398 mRNA 3'-end processing by stem-loop binding and cleavage
GO:0008334 histone mRNA metabolic process
GO:0031123 RNA 3'-end processing
GO:0031124 mRNA 3'-end processing
Molecular Function -
Cellular Component GO:0015030 Cajal body
GO:0016604 nuclear body
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-109688: Cleavage of Growing Transcript in the Termination Region
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-112297: Post-Elongation Processing of Intronless pre-mRNA
R-HSA-76044: Post-Elongation Processing of the Transcript
R-HSA-75067: Processing of Capped Intronless Pre-mRNA
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-73856: RNA Polymerase II Transcription Termination
R-HSA-77588: SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs
R-HSA-111367: SLBP independent Processing of Histone Pre-mRNAs
Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ZNF473 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ZNF473 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.56; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ZNF473 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1110.55
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2380.774
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.020.976
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0980.694
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3990.829
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2860.9
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0590.84
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0450.97
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1230.923
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0160.986
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3470.781
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2150.000939
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ZNF473 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ZNF473. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ZNF473. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ZNF473.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ZNF473. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ZNF473 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ZNF473 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolZNF473
Namezinc finger protein 473
Aliases KIAA1141; DKFZP434N043; HZFP100; ZN473; zfp-100; zinc finger protein 100 homolog; zinc finger protein ZFP100
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ZNF473 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.